Categories: Health

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Vera Therapeutics

BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera’s closing trading price on June 3, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

GlobeNews Wire

Recent Posts

Annature helps accounting firms and company directors manage corporate compliance fees with new product launch

BRISBANE, Australia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annature, Australia’s leading provider of digital signing…

1 hour ago

ROG Xbox Ally and ROG Xbox Ally X Now Available for Pre-Order in Canada

KEY POINTS Order now: Pre-orders for ROG Xbox Ally X and ROG Xbox Ally start…

1 hour ago

Kia advances EV Mobility experience with new Plug and Charge Technology

Kia Plug & Charge technology for seamless EV charging at compatible stations is coming soon1Available…

3 hours ago

Lamborghini Diablo: celebrating 35 years of an icon

Symbol of the 1990s, it elevated the concept of the super sports car thanks to…

3 hours ago

Advanced CAR-T Cell Therapy in a Young Engineer Battling High-Risk Pre-B Acute Lymphoblastic Leukemia

KOLKATA, India, Sept. 25, 2025 /PRNewswire/ -- In a major milestone for cancer care in…

3 hours ago

Vantage Foundation Partners with Laureus Sport for Good Foundation to Explore the Transformative Power of Sport for Vulnerable Youth

MADRID, Sept. 24, 2025 /PRNewswire/ -- Vantage Foundation is partnering with Laureus Sport for Good…

3 hours ago